Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 19/20 | 0.81 |
| ▸ | PRKDC | P78527 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2484717 | 0.90 | ATR (1.00) | ATRPRKDCATM | |
| SCHEMBL3979058 | 0.87 | ATR (0.76) | ATRPRKDCATM | |
| SCHEMBL4009915 | 0.85 | ATR (0.77) | ATRPRKDCATM | |
| SCHEMBL3467005 | 0.85 | ATR (0.69) | ATRPRKDCATM | |
| SCHEMBL2513432 | 0.84 | ATR (1.00) | ATRPRKDCATM | |
| SCHEMBL13138782 | 0.83 | ATR (0.77) | ATRPRKDCATM | |
| SCHEMBL13138778 | 0.83 | ATR (0.78) | ATRPRKDCATMKDM4E | |
| SCHEMBL3059386 | 0.83 | ATR (0.73) | ATRPRKDCATM | |
| SCHEMBL2510528 | 0.82 | ATR (1.00) | ATRPRKDCATM | |
| SCHEMBL3054972 | 0.81 | ATR (1.00) | ATRPRKDCATMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318472-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318472-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318472-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| US-7598251-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598251-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598251-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090062307-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062307-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062307-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-7459454-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459454-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459454-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1606266-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20060084651-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-20 | — | — | US | disclosed |
| EP-1606266-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004084813-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062307-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | STK25, ABL1, STK35 | ATR 223/4885PRKDC 89/4885ATM 82/4885 |
| US-20060084651-A1 | Chemical compounds | STK25, MAP3K5, STK35 | ATR 388/4885PRKDC 71/4885ATM 197/4885 |
| US-20090318472-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | STK25, ABL1, STK35 | ATR 223/4885PRKDC 89/4885ATM 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.